Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin vs Rosuvastatin in Type 2 Diabetes with ACS
NCT05306990Completed
- Sponsor
- Helwan University
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial in hypercholesterolemia comparing Atorvastatin with Rosuvastatin (2 arms). Primary endpoints: Mean Change from baseline in Low Density Lipoprotein Cholesterol at 12 weeks and 50% reduction in low-density lipoprotein cholesterol levels at 12 weeks. Started Apr 2017; status: completed.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05306990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306990.